Topic: neuroprotective effects

Alzheimer’s disease (AD) is a progressive age-associated brain disorder in which deficits in episodic memory function are among the first cognitive symptoms observed. Clinical findings indicate that AD patients are more susceptible to anesthesia-induced postoperative cognitive dysfunction, which is in line with the well-known fact that general anesthesia is more detrimental in the two extreme age groups, neonates/infants and the elderly. Alfaxalone (ALX) is the synthetic analog of allopregnanolone. It is currently in use only in veterinary practice as a fast-acting anesthetic with a high thera

Promising alternative strategies, such as repurposing drugs, have been considered for Parkinson’s Disease (PD). Within this framework, N-acetylcysteine (NAC) has shown promising results in preserving the dopaminergic system. Indeed, published data from our group revealed that NAC single-dose administration enhanced DAn viability, as we found that it could restore dopamine transporter (DAT) levels. With this in mind, we consider that NAC application could be a remarkable asset to approach PD. Therefore, in the present study, we addressed the impact of a 7-day treatment with NAC in a 6-hydroxydo

Acute ischemic stroke, also referred to as a cerebrovascular accident, occurs when localized tissue faces ischemia, leading to an inability to maintain physiological conditions or even resulting in death due to the obstruction or rupture of blood vessels in the brain. The current use of rt-PA for stroke medication has a limited time frame of 3-4.5 hours and is associated with neurotoxicity. Hence, there is an urgent need to explore alternative treatments for ischemic stroke. Cinchonidine, an alkaloid derived from the bark of cinchona, has previously demonstrated anti-inflammatory and antioxida